The Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for elamipretide for the treatment of Barth syndrome, a rare genetic disorder.

An FDA advisory committee may have ruled in elamipretide’s favor back in October, but it looks like Stealth BioTherapeutics ...

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose ...

CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a $20.8 billion biotechnology company with a robust 75.6% gross profit margin, ...

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA CAMBRIDGE, Mass., Jan. 2 ...

THE LAWSUIT: A class action securities lawsuit was filed against Applied Therapeutics, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between ...

Nutriband Inc. (NTRB) shares have surged to a 52-week high, reaching a price level of $9.6, with an impressive 80% gain just ...

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

BENGALURU/HYDERABAD (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories reported third-quarter profit below expectations on Thursday, hurt by pricing pressure in the competitive North American ...

Malawi breaking news publishing 24 hours a day news about Malawi, Malawi Business, Malawi Tourism, Malawi Politics, Malawi News ...

The grant money will be used to create new degree programs at Reynolds and Brightpoint community colleges to help develop the ...

Our hope is that we’re going to work as fast and as hard as possible to make sure that they can get access to the care that they need.” By Zach Wendling, Nebraska Examiner Three similar legislative ...